These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25655379)

  • 1. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
    Suzuki K; Ogura M; Abe Y; Suzuki T; Tobinai K; Ando K; Taniwaki M; Maruyama D; Kojima M; Kuroda J; Achira M; Iizuka K
    Int J Hematol; 2015 Mar; 101(3):286-94. PubMed ID: 25655379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
    Orlowski RZ; Gercheva L; Williams C; Sutherland H; Robak T; Masszi T; Goranova-Marinova V; Dimopoulos MA; Cavenagh JD; Špička I; Maiolino A; Suvorov A; Bladé J; Samoylova O; Puchalski TA; Reddy M; Bandekar R; van de Velde H; Xie H; Rossi JF
    Am J Hematol; 2015 Jan; 90(1):42-9. PubMed ID: 25294016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
    Voorhees PM; Manges RF; Sonneveld P; Jagannath S; Somlo G; Krishnan A; Lentzsch S; Frank RC; Zweegman S; Wijermans PW; Orlowski RZ; Kranenburg B; Hall B; Casneuf T; Qin X; van de Velde H; Xie H; Thomas SK
    Br J Haematol; 2013 May; 161(3):357-66. PubMed ID: 23432640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
    Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
    Takamatsu Y; Sunami K; Hata H; Nagafuji K; Choi I; Higuchi M; Uozumi K; Masaki Y; Tamura K;
    Int J Hematol; 2010 Oct; 92(3):503-9. PubMed ID: 20824401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
    Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
    Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
    San-Miguel J; Bladé J; Shpilberg O; Grosicki S; Maloisel F; Min CK; Polo Zarzuela M; Robak T; Prasad SV; Tee Goh Y; Laubach J; Spencer A; Mateos MV; Palumbo A; Puchalski T; Reddy M; Uhlar C; Qin X; van de Velde H; Xie H; Orlowski RZ
    Blood; 2014 Jun; 123(26):4136-42. PubMed ID: 24833354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
    Moreau P; Cavallo F; Leleu X; Hulin C; Amiot M; Descamps G; Facon T; Boccadoro M; Mignard D; Harousseau JL
    Leukemia; 2011 May; 25(5):872-4. PubMed ID: 21321571
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
    Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
    J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
    Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
    Wang LX; Lu H; Shen WY; Qian SX; Qiu HX; Wu HX; Zhang JF; Wu YJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):943-5. PubMed ID: 18718096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience.
    Igarashi N; Chou T; Hirose T; Imai Y; Ishiguro T
    Int J Hematol; 2010 Oct; 92(3):518-23. PubMed ID: 20886379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.